Opus Genetics Inc. (R3X1)
XMUN 
Summary
R3X1 Chart
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Opus Genetics Inc. Dividends
Opus Genetics Inc. Earnings
| 11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 6 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 6 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
Opus Genetics Inc. (R3X1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Opus Genetics Inc. ever had a stock split?
Opus Genetics Inc. Profile
| Biotechnology Industry | Healthcare Sector | George Magrath CEO | XMUN Exchange | US67577R1023 ISIN |
| US Country | 14 Employees | - Last Dividend | 6 Nov 2020 Last Split | 23 May 2005 IPO Date |
Overview
Ocuphire Pharma, Inc. is an ambitious clinical-stage ophthalmic biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of refractive and retinal eye disorders, striving to meet unfulfilled needs of patients worldwide. Founded in 2018 and based in Farmington Hills, Michigan, Ocuphire Pharma has focused its efforts on tackling some of the most challenging conditions affecting vision. By channeling their resources into the development of novel treatments, they aim to improve the quality of life for individuals suffering from these eye disorders.
Products and Services
At the heart of Ocuphire Pharma's innovative pipeline are several product candidates at various stages of clinical and preclinical development, including:
- Phentolamine Ophthalmic Solution: This solution is designed for the reversal of mydriasis. Currently, it is also advancing through Phase III clinical trials for treating presbyopia, as well as dim light or night vision disturbances. The aim of this product is to significantly improve visual acuity and functionality in conditions that affect millions worldwide.
- APX3330: Serving as the company's lead retinal product candidate, APX3330 is a small-molecule inhibitor targeting the reduction-oxidation effector factor-1 protein. Having completed a Phase II clinical trial, APX3330 shows promise for the treatment of diabetic retinopathy, a prevalent diabetic eye disease that can lead to significant visual impairment if left untreated.
- APX2009 and APX2014: These are preclinical product candidates currently being developed for various retina indications. These compounds represent Ocuphire Pharma’s commitment to expanding its portfolio and reaching more patients with innovative solutions for retinal disorders.
Contact Information
